52
Participants
Start Date
May 30, 2019
Primary Completion Date
August 16, 2022
Study Completion Date
October 27, 2022
KN046
KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
Nab-paclitaxel
Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
The First Affiliated Hospital of Xiamen University, Xiamen
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
Harbin Medical University Cancer Hospital, Harbin
Henan Cancer Hospital, Zhengzhou
Hunan Cancer Hospital, Changsha
Nantong Tumor Hospital, Nantong
JiLin Cancer Hospital, Changchun
Liaoning Cancer Hospital, Shenyang
LiaoCheng People's Hospital, Liaocheng
Zibo Municipal Hospital, Zibo
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
INDUSTRY